Zobrazeno 1 - 10 of 40 pro vyhledávání: '"Rhona, Maclean"'
1
Akademický článek
A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)
Autor: Laura Green, Joachim Tan, Joan K Morris, Raza Alikhan, Nicola Curry, Tamara Everington, Rhona Maclean, Khalid Saja, Simon Stanworth, Campbell Tait, Peter MacCallum
Publikováno v: Haematologica, Vol 103, Iss 4 (2018)
The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms
Externí odkaz: https://doaj.org/article/3cf72905fd4a4f8e8e8a84828a3232af
Zobrazit plný text záznamu
2
Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab
Autor: Annette Bowyer, Paula Brown, Barbara Hopkins, Marie Scully, Fiona Shepherd, Anna Lowe, Patrick Mensah, Rhona Maclean, Steve Kitchen, Joost J. Veen
Publikováno v: British journal of haematologyREFERENCES. 197(3)
Acquired immune thrombotic thrombocytopenic purpura (iTTP) is a rare disease with a poor prognosis if undiagnosed. It is caused by autoantibody production to the von Willebrand factor (VWF) cleaving protease, A disintegrin and metalloproteinase with
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff519068a1c1ad49968f1035d7384f1
https://pubmed.ncbi.nlm.nih.gov/35262910
Zobrazit plný text záznamu
4
Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A
Autor: Susan Guy, Fiona Shepherd, Sean Platton, Rhona Maclean, Steve Kitchen, Annette E. Bowyer
Publikováno v: Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 26(6)
Introduction Acquired haemophilia A (AHA) is a rare bleeding disorder caused by the development of autoantibodies to endogenous human factor VIII (hFVIII). If treatment of bleeding is required, one option is recombinant porcine FVIII (rpFVIII). Cross
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a48dec369b16135d486f3f894f1d7f
https://pubmed.ncbi.nlm.nih.gov/32997894
Zobrazit plný text záznamu
6
Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors
Autor: Annette E. Bowyer, Steve Kitchen, Rhona Maclean
Publikováno v: Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 26(3)
Introduction Emicizumab (Hemlibra, Roche-Chugai) is a recombinant humanized bispecific IgG4 antibody which mimics some of the actions of activated factor VIII (FVIIIa) by binding to factor X (FX) and activated factor IX (FIXa) to activate FX. Aim To
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ffacc19429c22e77da1269341be63d0
https://pubmed.ncbi.nlm.nih.gov/32249990
Zobrazit plný text záznamu
8
A three-year prospective study of the presentation and clinical outcomes of major bleeding episodes associated with oral anticoagulant use in the UK (ORANGE study)
Autor: Peter MacCallum, Tamara Everington, Laura E. Green, Joan K. Morris, Simon J. Stanworth, Nicola Curry, Raza Alikhan, Rhona Maclean, Campbell Tait, Khalid Saja, Joachim Tan
Publikováno v: Haematologica
The outcomes of patients developing major bleeding while on oral anticoagulants remain largely unquantified. The objectives of this study were to: (i) describe the burden of major hemorrhage associated with all available oral anticoagulants in terms
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c98027098666b22250df2b62af388c34
Zobrazit plný text záznamu
9
Limitation of the activated partial thromboplastin time as a monitoring method of the direct thrombin inhibitor argatroban
Autor: Steve Kitchen, J. J. Van Veen, Susan Guy, Rhona Maclean
Publikováno v: International Journal of Laboratory Hematology. 37:834-843
SummaryBackground Argatroban is licensed for patients with heparin-induced thrombocytopenia and monitoring is conventionally by activated partial thromboplastin time (APTT) ratio with a target of 1.5–3.0 and not exceeding 100 s. The APTT may be inf
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ff5b5e6517128ca990d2bc4b657dfef
https://doi.org/10.1111/ijlh.12414
Zobrazit plný text záznamu
10
Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes
Autor: Mary Underwood, Patrick O Brien, Fionnuala Ní Áinle, William Lester, Michael J. Nash, Marie Scully, Siobhan McGuckin, Katherine Langley, Henry G. Watson, Rosemary J. Scott, Mari Thomas, Rhona Maclean, Desmond Creagh, Raymond Camilleri, G. Evans, Ashok Roy, Rachel Rayment, Amanda Clark, Vickie McDonald
Publikováno v: Blood. 124:211-219
Pregnancy can precipitate thrombotic thrombocytopenic purpura (TTP). We present a prospective study of TTP cases from the United Kingdom Thrombotic Thrombocytopenic Purpura (UK TTP) Registry with clinical and laboratory data from the largest cohort o
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b545bb34f8956c47d06201b570e02cbf
https://doi.org/10.1182/blood-2014-02-553131
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje